Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Structural basis for ligand capture and release by the endocytic receptor ApoER2.

Hirai H, Yasui N, Yamashita K, Tabata S, Yamamoto M, Takagi J, Nogi T.

EMBO Rep. 2017 Jun;18(6):982-999. doi: 10.15252/embr.201643521. Epub 2017 Apr 26.

2.

Mechanistic insights into ectodomain shedding: susceptibility of CADM1 adhesion molecule is determined by alternative splicing and O-glycosylation.

Shirakabe K, Omura T, Shibagaki Y, Mihara E, Homma K, Kato Y, Yoshimura A, Murakami Y, Takagi J, Hattori S, Ogawa Y.

Sci Rep. 2017 Apr 10;7:46174. doi: 10.1038/srep46174.

3.

Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.

Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2016 Oct;35(5):254-258.

4.

Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/α-albumin.

Mihara E, Hirai H, Yamamoto H, Tamura-Kawakami K, Matano M, Kikuchi A, Sato T, Takagi J.

Elife. 2016 Feb 23;5. pii: e11621. doi: 10.7554/eLife.11621.

5.

Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state.

Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J.

J Cell Sci. 2016 Apr 1;129(7):1512-22. doi: 10.1242/jcs.176685. Epub 2016 Feb 12.

6.

CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.

Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.

Cancer Immunol Res. 2016 Mar;4(3):259-68. doi: 10.1158/2326-6066.CIR-15-0060. Epub 2016 Jan 28.

7.

A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.

Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y.

Biochem Biophys Res Commun. 2015 Oct 30;466(4):733-9. doi: 10.1016/j.bbrc.2015.09.070. Epub 2015 Sep 14.

PMID:
26381180
8.

Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Young MA, Deluca-Rapone L, Shienbaum AJ, Yin K, Jensen LD, Goldberg GS.

Oncotarget. 2015 Apr 20;6(11):9045-60.

9.

A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.

Liu X, Ogasawara S, Kaneko MK, Oki H, Hozumi Y, Goto K, Takagi M, Kato Y.

Biochem Biophys Res Commun. 2015 Apr 17;459(4):636-42. doi: 10.1016/j.bbrc.2015.02.162. Epub 2015 Mar 6.

PMID:
25753205
10.

A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.

Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y.

Structure. 2014 Dec 2;22(12):1711-1721. doi: 10.1016/j.str.2014.09.009. Epub 2014 Nov 6.

11.

A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.

Kato Y, Kaneko MK.

Sci Rep. 2014 Aug 1;4:5924. doi: 10.1038/srep05924.

12.

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.

Kato Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.

Cancer Sci. 2014 Jun;105(6):744-8. doi: 10.1111/cas.12413.

13.

PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin.

Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y, Takagi J.

Protein Expr Purif. 2014 Mar;95:240-7. doi: 10.1016/j.pep.2014.01.009. Epub 2014 Jan 28.

PMID:
24480187
14.

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.

Cancer Med. 2013 Dec;2(6):803-14. doi: 10.1002/cam4.149. Epub 2013 Oct 17.

15.

Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.

Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):377-81. doi: 10.1089/mab.2013.0050.

PMID:
24328739
16.

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.

J Immunol. 2013 Jun 15;190(12):6239-49. doi: 10.4049/jimmunol.1300448. Epub 2013 May 20.

17.

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.

Kato Y, Kaneko MK.

Biochem Biophys Res Commun. 2013 Apr 19;433(4):374-8. doi: 10.1016/j.bbrc.2013.02.106. Epub 2013 Mar 20.

PMID:
23524262
18.

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.

Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y.

Biochem Biophys Res Commun. 2013 Mar 1;432(1):40-5. doi: 10.1016/j.bbrc.2013.01.088. Epub 2013 Jan 31.

PMID:
23376717
19.

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.

Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.

Int J Cancer. 2013 May 15;132(10):2339-48. doi: 10.1002/ijc.27919. Epub 2012 Nov 23.

20.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x. Epub 2012 Aug 27.

Supplemental Content

Loading ...
Support Center